PubMed:1720382 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":752,"end":759},"obj":"HP_0002664"},{"id":"T2","span":{"begin":830,"end":847},"obj":"HP_0010788"},{"id":"T3","span":{"begin":841,"end":847},"obj":"HP_0002664"},{"id":"T4","span":{"begin":1134,"end":1156},"obj":"HP_0030357"},{"id":"T5","span":{"begin":1145,"end":1156},"obj":"HP_0100526"},{"id":"T6","span":{"begin":1150,"end":1156},"obj":"HP_0002664"},{"id":"T7","span":{"begin":1175,"end":1182},"obj":"HP_0002664"},{"id":"T8","span":{"begin":1202,"end":1220},"obj":"HP_0012189"},{"id":"T9","span":{"begin":1212,"end":1220},"obj":"HP_0002665"},{"id":"T10","span":{"begin":1226,"end":1240},"obj":"HP_0100615"},{"id":"T11","span":{"begin":1234,"end":1240},"obj":"HP_0002664"},{"id":"T12","span":{"begin":1343,"end":1369},"obj":"HP_0030358"},{"id":"T13","span":{"begin":1347,"end":1369},"obj":"HP_0030357"},{"id":"T14","span":{"begin":1358,"end":1369},"obj":"HP_0100526"},{"id":"T15","span":{"begin":1363,"end":1369},"obj":"HP_0002664"},{"id":"T16","span":{"begin":1377,"end":1397},"obj":"HP_0030448"},{"id":"T17","span":{"begin":1389,"end":1397},"obj":"HP_0100242"},{"id":"T18","span":{"begin":1438,"end":1453},"obj":"HP_0030079"},{"id":"T19","span":{"begin":1447,"end":1453},"obj":"HP_0002664"},{"id":"T20","span":{"begin":1551,"end":1564},"obj":"HP_0003002"},{"id":"T21","span":{"begin":1551,"end":1564},"obj":"HP_0100013"},{"id":"T22","span":{"begin":1558,"end":1564},"obj":"HP_0002664"},{"id":"T23","span":{"begin":1578,"end":1593},"obj":"HP_0030079"},{"id":"T24","span":{"begin":1587,"end":1593},"obj":"HP_0002664"},{"id":"T25","span":{"begin":1929,"end":1945},"obj":"HP_0001873"},{"id":"T26","span":{"begin":1996,"end":2006},"obj":"HP_0001262"},{"id":"T27","span":{"begin":2011,"end":2020},"obj":"HP_0001289"},{"id":"T28","span":{"begin":2031,"end":2045},"obj":"HP_0001298"},{"id":"T29","span":{"begin":2050,"end":2054},"obj":"HP_0001259"},{"id":"T30","span":{"begin":2380,"end":2388},"obj":"HP_0001596"},{"id":"T31","span":{"begin":2394,"end":2409},"obj":"HP_0002017"},{"id":"T32","span":{"begin":2394,"end":2400},"obj":"HP_0002018"},{"id":"T33","span":{"begin":2401,"end":2409},"obj":"HP_0002013"},{"id":"T34","span":{"begin":2906,"end":2923},"obj":"HP_0010788"},{"id":"T35","span":{"begin":2917,"end":2923},"obj":"HP_0002664"},{"id":"T36","span":{"begin":3006,"end":3012},"obj":"HP_0002664"},{"id":"T1","span":{"begin":752,"end":759},"obj":"HP_0002664"},{"id":"T2","span":{"begin":830,"end":847},"obj":"HP_0010788"},{"id":"T3","span":{"begin":841,"end":847},"obj":"HP_0002664"},{"id":"T4","span":{"begin":1134,"end":1156},"obj":"HP_0030357"},{"id":"T5","span":{"begin":1145,"end":1156},"obj":"HP_0100526"},{"id":"T6","span":{"begin":1150,"end":1156},"obj":"HP_0002664"},{"id":"T7","span":{"begin":1175,"end":1182},"obj":"HP_0002664"},{"id":"T8","span":{"begin":1202,"end":1220},"obj":"HP_0012189"},{"id":"T9","span":{"begin":1212,"end":1220},"obj":"HP_0002665"},{"id":"T10","span":{"begin":1226,"end":1240},"obj":"HP_0100615"},{"id":"T11","span":{"begin":1234,"end":1240},"obj":"HP_0002664"},{"id":"T12","span":{"begin":1343,"end":1369},"obj":"HP_0030358"},{"id":"T13","span":{"begin":1347,"end":1369},"obj":"HP_0030357"},{"id":"T14","span":{"begin":1358,"end":1369},"obj":"HP_0100526"},{"id":"T15","span":{"begin":1363,"end":1369},"obj":"HP_0002664"},{"id":"T16","span":{"begin":1377,"end":1397},"obj":"HP_0030448"},{"id":"T17","span":{"begin":1389,"end":1397},"obj":"HP_0100242"},{"id":"T18","span":{"begin":1438,"end":1453},"obj":"HP_0030079"},{"id":"T19","span":{"begin":1447,"end":1453},"obj":"HP_0002664"},{"id":"T20","span":{"begin":1551,"end":1564},"obj":"HP_0003002"},{"id":"T21","span":{"begin":1551,"end":1564},"obj":"HP_0100013"},{"id":"T22","span":{"begin":1558,"end":1564},"obj":"HP_0002664"},{"id":"T23","span":{"begin":1578,"end":1593},"obj":"HP_0030079"},{"id":"T24","span":{"begin":1587,"end":1593},"obj":"HP_0002664"},{"id":"T25","span":{"begin":1929,"end":1945},"obj":"HP_0001873"},{"id":"T26","span":{"begin":1996,"end":2006},"obj":"HP_0001262"},{"id":"T27","span":{"begin":2011,"end":2020},"obj":"HP_0001289"},{"id":"T28","span":{"begin":2031,"end":2045},"obj":"HP_0001298"},{"id":"T29","span":{"begin":2050,"end":2054},"obj":"HP_0001259"},{"id":"T30","span":{"begin":2380,"end":2388},"obj":"HP_0001596"},{"id":"T31","span":{"begin":2394,"end":2409},"obj":"HP_0002017"},{"id":"T32","span":{"begin":2394,"end":2400},"obj":"HP_0002018"},{"id":"T33","span":{"begin":2401,"end":2409},"obj":"HP_0002013"},{"id":"T34","span":{"begin":2906,"end":2923},"obj":"HP_0010788"},{"id":"T35","span":{"begin":2917,"end":2923},"obj":"HP_0002664"},{"id":"T36","span":{"begin":3006,"end":3012},"obj":"HP_0002664"}],"text":"Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.\nIfosfamide is an oxazaphosphorine alkylating agent with a broad spectrum of antineoplastic activity. It is a prodrug metabolised in the liver by cytochrome P450 mixed-function oxidase enzymes to isofosforamide mustard, the active alkylating compound. Mesna, a uroprotective thiol agent, is routinely administered concomitantly with ifosfamide, and has almost eliminated ifosfamide-induced haemorrhagic cystitis and has reduced nephron toxicity. Therapeutic studies, mostly noncomparative in nature, have demonstrated the efficacy of ifosfamide/mesna alone, or more commonly as a component of combination regimens, in a variety of cancers. In patients with relapsed or refractory disseminated nonseminomatous testicular cancer, a salvage regimen of ifosfamide/mesna, cisplatin and either etoposide or vinblastine produced complete response in approximately one-quarter of patients. As a component of both induction and salvage chemotherapeutic regimens, ifosfamide/mesna has produced favourable response rates in small cell lung cancer, paediatric solid tumours, non-Hodgkin's and Hodgkin's lymphoma, and ovarian cancer. Induction therapy with ifosfamide/mesna-containing chemotherapeutic regimens has been encouraging in non-small cell lung cancer, adult soft-tissue sarcomas, and as neoadjuvant therapy in advanced cervical cancer. As salvage therapy, ifosfamide/mesna-containing combinations have a palliative role in advanced breast cancer and advanced cervical cancer. Ifosfamide/mesna can elicit responses in patients refractory to numerous other antineoplastic drugs, including cyclophosphamide. With administration of concomitant mesna to protect against ifosfamide-induced urotoxicity, the principal dose-limiting toxicity of ifosfamide is myelosuppression; leucopenia is generally more severe than thrombocytopenia. Reversible CNS adverse effects ranging from mild somnolence and confusion to severe encephalopathy and coma can occur in approximately 10 to 20% of patients after intravenous infusion, and the incidence of neurotoxicity may be increased to 50% after oral administration because of differences in the preferential route of metabolism between the 2 routes of administration. Other adverse effects of ifosfamide include nephrotoxicity, alopecia, and nausea/vomiting. In general, intravenously administered mesna is associated with a low incidence of adverse effects; however, gastrointestinal disturbances are common following oral administration. Thus, ifosfamide/mesna is an important and worthwhile addition to the currently available range of chemotherapeutic agents. It has a broad spectrum of antineoplastic activity and causes less marked myelosuppression than many other cytotoxic agents. At present, the role of ifosfamide/mesna in refractory germ cell testicular cancer is clearly defined; however, its overall place in the treatment of other forms of cancer awaits delineation in future well-controlled comparative studies."}